Skip to main content

Table 1 Schedule of enrolment, interventions, and assessments

From: Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial

  

Study period

 

allocation

post allocation

Study visit number

1

1

2

3

4

5

Age (months)

1

1

2

4

6

7

Eligibility screen

x

     

Informed consent signed

x

     

Randomisation

x

     

Interventions – Pneumococcal conjugate vaccines

 Prevenar13 (_PPP)

 

_

P

P

P

 

 Synflorix (_SSS)

 

_

S

S

S

 

 COMBO (SSSP)

 

S

S

S

P

 

 RotarixR

  

x

x

  

 InfanrixR Hexa

  

x

x

x

 

Outcome assessments

 Risk factor data and interviews

      

 Fixed e.g. sex, birthweight, gestational age, maternal education

x

     

 Not fixed e.g. household occupancy, smoke exposure, breastfeeding

x

   

x

 

 Blood draw (heel, finger prick, or venepuncture)

  

x*

x*

 

x

 Ear assessment

      

 Tympanometry

 

x

x

x

x

x

 Video otoscopy

   

x

x

x

 Nasopharyngeal swab

 

x

x

x

x

 General health (skin, chest, nose, temp, weight, length) and medical record review

 

x

x

x

x

x

  1. Note: Outcomes of all procedures will be published in separate reports
  2. *blood draw occurs at either 2 months or 4 months of age (decided by a random process). § NP swab collection at one month of age commenced late 2014 (NT) or 2015 (WA). S is PHiD-CV10 (Synflorix™). P is PCV13 (Prevenar13™)
  3. PCV13 contains serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, and 23F
  4. PHiD-CV10 contains serotypes 1, 4, 5, 6B, 7F, 9 V, 14, 18C, 19F, 23F, and protein D of non-typeable Haemophilus influenzae